Startup Funding News
Explore funding rounds, the companies behind them and the investors taking part.
- Rounds
- 473 All time
- Disclosed funding
- $19.6B 400 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| SM Superluminal MedicinesCompany profile Superluminal Medicines combines structural biology, protein dynamics, machine learning and experimental testing to discover small-molecule drugs for difficult G protein-coupled receptor targets. Its pipeline focuses on endocrine and cardiometabolic diseases, including rare genetic and hypothalamic obesity. Superluminal Medicines combines structural biology, protein dynamics, machine learning and experimental testing to discover small-molecule drugs for difficult G protein-coupled receptor targets. Its pipeline focuses on endocrine and cardiometabolic diseases, including rare genetic and hypothalamic obesity. | $60M | Series B | Biotech | United States | Investors | |
| T TensiveCompany profile Clinical-stage bioresorbable implants designed to support natural breast-tissue regeneration and mark the tumour bed after lumpectomy. Clinical-stage bioresorbable implants designed to support natural breast-tissue regeneration and mark the tumour bed after lumpectomy. | ≤€20M | Convertible venture debtUndisclosed | Biotech, Healthtech | Italy | Investors | |
| ST SiccaNova TherapeuticsCompany profile A biotechnology company developing an oral drug candidate for dry mouth and related gland-function disorders. A biotechnology company developing an oral drug candidate for dry mouth and related gland-function disorders. | ¥1.3B | Series A | Biotech | Japan | Investors | |
| TT Typewriter TherapeuticsCompany profile Typewriter Therapeutics is developing an all-RNA gene-writing platform that inserts therapeutic genes at a defined genomic site without viral vectors or double-strand DNA breaks. Its programs target in vivo engineered CAR-T cells and gene insertion for severe genetic diseases, including liver disorders. Typewriter Therapeutics is developing an all-RNA gene-writing platform that inserts therapeutic genes at a defined genomic site without viral vectors or double-strand DNA breaks. Its programs target in vivo engineered CAR-T cells and gene insertion for severe genetic diseases, including liver disorders. | $56M | Series A | Biotech | United States | Investors | |
 DorothCompany profile Doroth develops lab-on-a-chip molecular tests and monitoring services that help agricultural businesses detect plant pathogens and track biological crop treatments closer to where decisions are made. Doroth develops lab-on-a-chip molecular tests and monitoring services that help agricultural businesses detect plant pathogens and track biological crop treatments closer to where decisions are made. | $4.5M | Funding roundUndisclosed | Biotech, Agritech | Brazil | Investors | |
| D DataHowCompany profile DataHow builds DataHowLab, a process-modeling and digital-twin platform for biopharmaceutical process engineers and manufacturers. DataHow builds DataHowLab, a process-modeling and digital-twin platform for biopharmaceutical process engineers and manufacturers. | Undisclosed | Bridge financingUndisclosed | Biotech, Enterprise software | Switzerland | Investors | |
| NT NovaGo TherapeuticsCompany profile NovaGo Therapeutics is a clinical-stage biotech developing anti-Nogo-A antibodies intended to promote nerve regeneration and functional recovery after central nervous system injury. NovaGo Therapeutics is a clinical-stage biotech developing anti-Nogo-A antibodies intended to promote nerve regeneration and functional recovery after central nervous system injury. | CHF 24M | Series B | Biotech | Switzerland | Investors | |
| AT Amyl TherapeuticsCompany profile Amyl Therapeutics is developing immunotherapies that target amyloid aggregates linked to neurodegenerative disease. Amyl Therapeutics is developing immunotherapies that target amyloid aggregates linked to neurodegenerative disease. | €8.3M | Series A extensionSeries A | Biotech | Belgium | Investors | |
| IT IntraGel Therapeutics, Ltd.Company profile IntraGel Therapeutics develops SRGel, a solvent-free injectable formulation designed to release drugs gradually from a single administration. IntraGel Therapeutics develops SRGel, a solvent-free injectable formulation designed to release drugs gradually from a single administration. | $7M | Strategic investmentUndisclosed | Biotech | Israel | Investors | |
| S SenticellCompany profile Senticell is developing a liquid-biopsy diagnostic based on nucleic acids associated with red blood cells. Senticell is developing a liquid-biopsy diagnostic based on nucleic acids associated with red blood cells. | $7M | Seed | Biotech | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · All time
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
22rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.
Browse rounds by topic
Geography
Featured selections
Nordic Foodtech Fund II pairs early capital with scientific expertise
An EIF pledge of up to €30m supports a fund targeting €80m for science-led agrifood companies.
Read the research →